Increased serum concentrations of soluble tumor necrosis factor receptor I in noncachectic and cachectic patients with advanced gastric and colorectal cancer

Surgery Today

Volumn 28, Issue 9, 1998, Pages 884-888

  Shibata, Masahiko ^a   Takekawa, Motoo ^a   Amano, Sadao ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Gastric cancer; Macrophage; Tumor immunology; Tumor necrosis factor

Indexed keywords

CD3 ANTIGEN; IMMUNOSUPPRESSIVE ACID PROTEIN; INTERLEUKIN 2 RECEPTOR; PREALBUMIN; RETINOL BINDING PROTEIN; TRANSFERRIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADVANCED CANCER; ARTICLE; CACHEXIA; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; STOMACH CANCER;

ANTIGENS, CD; CACHEXIA; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM PROTEINS; NUTRITION ASSESSMENT; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; REFERENCE VALUES; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0031688034     PISSN: 09411291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005950050247     Document Type: Article

References (34)

1. Lawson DH, Richmond A, Nixon DW, Rudman D (1982) Metabolic approaches to cancer cachexia. Annu Rev Nutr 2:277-301
2. Van Eys J (1985) Nutrition and cancer: physiological interrelationships. Annu Rev Nutr 5:435-461
3. Wesdorp RIC, Krause R, Von Meyenfeldt M (1983) Cancer cachexia and its nutritional implications. Br J Surg 70:352-355
4. Kern AK, Norton JA (1988) Cancer cachexia. J Parent Enteral Nutr 12:286-298
5. Moldawer LL, Georgieff M, Lundholm K (1987) Interleukin 1, tumour necrosis factor-α (cachectin) and the pathogenesis of cancer cachexia. Clin Physiol 7:263-274
6. Oliff A (1988) The role of tumor necrosis factor (cachectin) in cachexia. Cell 54:141-142
7. Beutler B, Greenwalt D, Humes JD, Chang M, Pan Y-CE, Mathison J, Ulevitch R, Cerami A (1985) Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature 316:552-554
8. Cerami A, Ikeda Y, Le Trang N, Hotez PJ, Beutler B (1985) Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett 11:173-177
9. Tartaglia LA, Goeddel DV (1992) Two TNF receptors. Immunol Today 13:151-153
10. Engelmann H-P, Novick D, Wallach D (1990) Tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 265:1531-1536
11. Engelmann H, Holtmann H, Brakebusch C, Avni YS, Sarov I, Naphar Y, Hadas E, Leitner O, Wallach D (1990) Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 265:14497-14504
12. Nophar Y, Kemper O, Brakebusch C, Engelmann H, Zwang R, Aderka D, Holtmann H, Wallach D (1990) Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned suing amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 9:3269-3278
13. Porteu F, Nathan C (1990) Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 172:599-607
14. Lantz M, Gullberg U, Nilsson E, Olsson I (1990) Characterization in vitro of a human tumor necrosis factor binding protein: a soluble form of a tumor necrosis factor receptor. J Clin Invest 86:1396-1402
15. Van Ostade X, Vandenabeele P, Everaerdt B, Loetscher H, Gentz R, Brockhaus M, Lesslauer W, Tavernier J, Brockaert P, Fiers W (1993) Human TNF mutants with selective activity on the p55 receptor. Nature 361:266-269
16. Hahn T, Toker L, Budilovsky S, Aderka D, Eshhar Z, Wallach D (1985) Use of a monoclonal antibody of a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein. Proc Natl Acad Sci USA 82:3814-3818
17. Nophar Y, Holtmann H, Ber R, Wallach D (1988) Dominance of resistance to the cytocidal effect of tumor necrosis factor in heterokaryons formed by fusion of resistant and sensitive cells. J Immunol 140:3456-3460
18. Wallach D, Holtmann H, Engelmann H, Nophar Y (1988) Sensitization and desensitization to lethal effects of tumor necrosis factor and of interleukin-1. J Immunol 140:2994-2999
19. Japanese Research Society for Cancer of the Stomach (1993) General rules for clinical and pathological studies on cancer of the stomach (12th edn.) Kanehara, Tokyo
20. Japanese Research Society for Cancer of the Colon and Rectum (1994) General rules for clinical and pathological studies on cancer of the colon, rectum and anus (5th edn.) Kanehara, Tokyo
21. Langkopf F, Atzpodien J (1994) Soluble tumour necrosis factor receptors as prognostic factors in cancer patients. Lancet 344:57-58
22. Aderka D, Engelmann H, Hornik V, Skornik Y, Levo Y, Wallach D, Kushtai G (1991) Increased serum levels of soluble forms for tumor necrosis factor in cancer patients. Cancer Res 51:5602-5607
23. Brivio F, Lissoni P, Mancini D (1991) Effect of antitumor surgery on soluble interleukin-2 receptor serum levels. Am J Surg 161:466-469
24. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boulin B, Yarchoan R, Nelson DL (1985) Soluble interleukin 2 receptors are released by activated human lymphoid cells in vitro. J Immunol 135:3172-3176
25. Rovelli F, Lissoni P, Crispino S (1988) Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study. Tumori 74:633-637
26. Denz H, Orth B, Weiss G, Herrmann R, Huber P, Wachter H Fuchs D (1993) Weight loss in patients with hematological neoplasias is associated with immune system stimulation. Clin Invest 71:37-41
27. Olsson I, Lantz M, Nilsson E, Peetre C, Thysell H, Grubb A, Adolf G (1989) Isolation and characterization of a tumor necrosis binding protein from urine. Eur J Haematol 42:270-275
28. Rogy MA, Coyle SM, Oldenburg HSA, Rock CS, Barie PS, Van Zee KJ, Smith CG, Moldawer LL, Lowry SF (1994) Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg 178:132-138
29. Engelmann E, Aderka D, Rubinstein M, Rotmann D, Wallach D (1989) A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 264:11974-11980
30. Seckinger P, Isaaz S, and Daye, J-M (1989) Purification and biologic characterization of a specific tumor necrosis factor inhibitor. J Biol Chem 264:11966-11973
31. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 89:4845-4849
32. Billiau A (1988) γ-interferon: the match that lights the fire? Immunol Today 9:37-40
33. Patton JS, Shepard HM, Wilking H, Lewis G, Aggarwal BB, Eessalu TE, Gavin LA, Grunfeld C (1986) Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. Proc Natl Acad Sci USA 83:8313-8317
34. Langstein HN, Doherty GM, Fraker DL, Buresh GM, Norton JA (1991) The roles of γ-interferon and tumor necrosis factor α in an experimental rat model of cancer cachexia. Cancer Res 51: 2302-2306